Atezolizumab for locally advanced or metastatic PD-L1-selected NSCLC
Atezolizumab for locally advanced or metastatic PD-L1-selected NSCLC
Rova-T: First ‘targeted’ treatment for small cell lung cancer shows promise
Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC
Latest in lung cancer from ECC 2015
Tackling global radiotherapy shortfall could save millions of lives and boost the economy of poorer countries
The p-medicine project and ECRIN
Highlights of the p-medicine project
Banking on biomarkers – improving the diagnosis of early stage NSCLC
Moving precision medicine for lung cancer into the adjuvant setting
SPRING – rolling tri-therapy combinations of targeted drugs in second line of metastatic NSCLC
SPECTAlung: improving clinical trial access for patients with thoracic tumours
PDL1 expression in thymic tumours